These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 30054832

  • 1. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
    Dong B, Liang Z, Chen Z, Li B, Zheng L, Yang J, Zhou H, Qu L.
    Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
    [Abstract] [Full Text] [Related]

  • 2. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Ge Y, Yang B, Xu X, Dai Q, Chen Z, Cheng R.
    Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
    [Abstract] [Full Text] [Related]

  • 3. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA, Jusoh SA, Yong AC, Asan JM, Hassan R, Johan MF.
    Asian Pac J Cancer Prev; 2014 Mar; 15(11):4555-61. PubMed ID: 24969884
    [Abstract] [Full Text] [Related]

  • 4. Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.
    Yin L, Xu J, Wu W, Niu M, Li Z, Zhu F, Xu K.
    Hematology; 2023 Dec; 28(1):2224625. PubMed ID: 37345979
    [Abstract] [Full Text] [Related]

  • 5. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
    Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P.
    Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
    [Abstract] [Full Text] [Related]

  • 6. Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.
    Cheng R, Huang Y, Fang Y, Wang Q, Yan M, Ge Y.
    Pharm Biol; 2021 Dec; 59(1):893-903. PubMed ID: 34214017
    [Abstract] [Full Text] [Related]

  • 7. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
    Wang XY, Sun GB, Wang YJ, Yan F.
    Biol Pharm Bull; 2020 Dec; 43(10):1526-1533. PubMed ID: 32999163
    [Abstract] [Full Text] [Related]

  • 8. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
    Waight JD, Banik D, Griffiths EA, Nemeth MJ, Abrams SI.
    J Biol Chem; 2014 May 30; 289(22):15642-52. PubMed ID: 24753251
    [Abstract] [Full Text] [Related]

  • 9. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
    Cheng Y, Hao Y, Zhang A, Hu C, Jiang X, Wu Q, Xu X.
    Int J Mol Med; 2018 Jan 30; 41(1):455-463. PubMed ID: 29115375
    [Abstract] [Full Text] [Related]

  • 10. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).
    Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, Ganser A, Eder M.
    Blood; 2006 Apr 15; 107(8):3279-87. PubMed ID: 16278304
    [Abstract] [Full Text] [Related]

  • 11. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
    Xu X, Zhang X, Liu Y, Yang L, Huang S, Lu L, Wang S, Guo Q, Zhao L.
    Oncotarget; 2016 Apr 26; 7(17):24436-54. PubMed ID: 27027438
    [Abstract] [Full Text] [Related]

  • 12. Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.
    Trécul A, Morceau F, Gaigneaux A, Orsini M, Chateauvieux S, Grandjenette C, Dicato M, Diederich M.
    Cancer Lett; 2013 Oct 28; 340(1):30-42. PubMed ID: 23811288
    [Abstract] [Full Text] [Related]

  • 13. MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5.
    Jiang X, Cheng Y, Hu C, Zhang A, Ren Y, Xu X.
    Leuk Lymphoma; 2019 Jul 28; 60(7):1709-1720. PubMed ID: 30516071
    [Abstract] [Full Text] [Related]

  • 14. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S, Meli M, Di Cristina A, Ferro A, Pipitone MR, Romagnoli R, Simoni D, Dieli F, Tolomeo M.
    Anticancer Drugs; 2013 Apr 28; 24(4):384-93. PubMed ID: 23370613
    [Abstract] [Full Text] [Related]

  • 15. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP, Hanumanthu PL, Malarvizhi GL, Prabhu R, Sidharthan N, Thampi MV, Menon D, Mony U, Menon K, Keechilat P, Nair S, Koyakutty M.
    Mol Pharm; 2012 Nov 05; 9(11):3062-78. PubMed ID: 22971013
    [Abstract] [Full Text] [Related]

  • 16. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
    Guerra B, Martín-Rodríguez P, Díaz-Chico JC, McNaughton-Smith G, Jiménez-Alonso S, Hueso-Falcón I, Montero JC, Blanco R, León J, Rodríguez-González G, Estévez-Braun A, Pandiella A, Díaz-Chico BN, Fernández-Pérez L.
    Oncotarget; 2017 May 02; 8(18):29679-29698. PubMed ID: 27557509
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
    Mencalha AL, Corrêa S, Salles D, Du Rocher B, Santiago MF, Abdelhay E.
    BMC Cancer; 2014 Nov 23; 14():866. PubMed ID: 25417721
    [Abstract] [Full Text] [Related]

  • 18. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
    Li X, Miao H, Zhang Y, Li W, Li Z, Zhou Y, Zhao L, Guo Q.
    Arch Toxicol; 2015 Jan 23; 89(1):121-36. PubMed ID: 24671465
    [Abstract] [Full Text] [Related]

  • 19. Dehydrocostus Lactone Suppresses Proliferation of Human Chronic Myeloid Leukemia Cells Through Bcr/Abl-JAK/STAT Signaling Pathways.
    Cai H, Qin X, Yang C.
    J Cell Biochem; 2017 Oct 23; 118(10):3381-3390. PubMed ID: 28300289
    [Abstract] [Full Text] [Related]

  • 20. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
    Niu CC, Zhao C, Yang ZD, Zhang XL, Wu WR, Pan J, Zhao C, Li ZQ, Ding W, Yang Z, Si WK.
    Int J Mol Med; 2013 Feb 23; 31(2):453-8. PubMed ID: 23233089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.